Clinical Trial Finder

Inclusion Criteria:

• - Present with chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris for at least 6 months prior to baseline.

• - Have ≥10% BSA involvement at screening and baseline.

• - Have both an sPGA score ≥3 and PASI score ≥12 at screening and baseline.

• - Are candidates for phototherapy and/or systemic therapy.

Exclusion Criteria:

• - Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline.

• - Drug-induced psoriasis.

• - Ongoing use of prohibited treatments.

• - Have previously completed or withdrawn from this study, or have previously exposed to ixekizumab or any other biologic drug directly targeting interleukin-17 (IL-17) (such as secukinumab) or the IL-17 receptor.

• - Have concurrent or recent use of any biologic agent within washout periods or <5 half-lives prior to baseline, whichever is longer.

• - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

Study I1F-MC-RHBH is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study examining the effect of 2 dose regimens of ixekizumab versus placebo in participants with moderate-to-severe plaque psoriasis (Ps) during an induction dosing period with dosing for 12 weeks and the primary endpoint measured at 12 weeks, followed by a randomized, 48-week maintenance dosing period. During the maintenance dosing period, the study will evaluate the maintenance of response/remission, as well as relapse or rebound following treatment withdrawal, and response to retreatment following relapse.